期刊文献+

结肠癌耐药细胞株LoVo/5-FU的建立及其差异表达基因的筛选 被引量:3

Establishment and selection of genes expressing differently in a human colon carcinoma LoVo/5-FU cell line
下载PDF
导出
摘要 目的:建立结肠癌细胞耐药模型LoVo/5-FU并初步筛选可能的耐药相关基因.方法:采用5-FU浓度递增法建立人结肠癌细胞耐药模型LoVo/5-FU,观察其生长规律并绘制细胞生长曲线:用MTT法鉴定耐药细胞株耐药性并计算耐药指数(RI);用基因芯片技术检测耐药细胞株LoVo/5-FU与其亲本细胞株LoVo中的差异表达基因,从中筛选出可能的耐药相关基因;用半定量RT-PCR方法对筛选出的部分耐药相关基因在耐药细胞及其亲本细胞中的表达情况进行验证.结果:LoVo/5-FU细胞与LoVo细胞相比,生长缓慢,细胞体积增大.LoVo/5-FU对5-FU、ADM、MMC耐药,而对CDDP无耐药性(RI:7.69,2.78,1.43和0.96).通过基因芯片筛选出差异表达基因425个,可能的耐药相关基因包括CYP1B1,NAT2,RNF20,SNAI2,MAP3K2,其中CYP1B1在LoVo/5-FU与LoVo中的表达有明显差异(Cy5/Cv3=5.877).结论:LoVo/5-FU细胞株耐药性稳定,耐药机制可能与CYP1B1,NAT2等耐药相关基因有关. AIM: To establish a Lovo/5-FU of human drugresistance colon carcinoma cell line, and to screen possible drug resistance-associated genes. METHODS: LoVo/5-FU of a human drug-resistance colon carcinoma cell line was induced by continuously exposing human colon carcinoma cells to gradually increasing concentrations of 5-FU. The growth law was observed and the growth curve protracted. The drug resistance of LoVo/5-FU was measured by MTT assay and the drug resistant index (RI) was calculated. Genes expressing differently between LoVo/5-FU and its parent cell line Lovo were screened using a gene chip, and several selected associated drug resistance genes were confirmed by reverse transcription-polyrnerase chain reaction (RT-PCR). RESULTS: Compared with parental cells, the resistance cell line had a slower growth rate and larger morphology. The LoVo/5-FU cell line showed drug resistance to 5-FU, adriarnycin (ADM), mitomycin (MMC), but not to cisplatin (CDDP) (RI: 7.69, 2.78, 1.43, and 0.96). There were 425 differently expressed genes associated with drug resistance by the gene chip screening method. The possible drug resistance-related genes included CYPIB1, NAT2, RNF20, SNAI2, and MAP3K2. The expression of CYPIB1 had a significant difference between the LoVo/5- FU cell line and the parent cell line (Cy5/Cy3 = 5.877). RT-PCR results were consistent with the gene chip results. CONCLUSION: The altered biological properties of LoVo/5-FU may be related to its drug resistance phenotype. Several genes, such as CY- PIB1, are possibly involved in the mechanism of drug resistance.
出处 《世界华人消化杂志》 CAS 北大核心 2007年第17期1899-1904,共6页 World Chinese Journal of Digestology
关键词 结肠癌 耐药相关基因 5-氟尿嘧啶 LoVo/5-FU细胞株 MTT法 基因芯片 逆转录-聚合酶链反应 Human colon carcinoma Drug resistance-related genes 5-fluorouracil LoVo/5-FU cell lines MTT assay Gene chip Reverse transcription polymerase chain reaction
  • 相关文献

参考文献33

  • 1Sharp L,Little J.Polymorphisms in genes involved in folate metabolism and colorectal neoplasia:a HuGE review.Am J Epidemiol 2004; 159:423-443.
  • 2Belvedere O,Puglisi F,Di Loreto C,Cataldi P,Guglielmi A,Aschele C,Sobrero A.Lack of correlation between immunohistochemical expression of E2F-1,thymidylate synthase expression and clinical response to 5-fluorouracil in advanced colorectal cancer.Ann Oncol 2004; 15:55-58.
  • 3姜浩,江骥,胡蓓.二氢嘧啶脱氢酶和胸腺嘧啶核苷激酶的研究进展[J].中国临床药理学杂志,2002,18(4):317-320. 被引量:6
  • 4Donnelly JG.Pharmacogenetics in cancer chemotherapy:balancing toxicity and response.Ther Drug Monit 2004; 26:231-235.
  • 5Sohn KJ,Smirnakis F,Moskovitz DN,Novakovic P,Yates Z,Lucock M,Croxford R,Kim YI.Effects of folylpolyglutamate synthetase modulation on chemosensitivity of colon cancer cells to 5-fluorouracil and methotrexate.Gut 2004; 53:1825-1831.
  • 6刘诚明,谌宏敏.基因芯片技术在肿瘤耐药研究中的应用[J].现代肿瘤医学,2003,11(5):390-392. 被引量:3
  • 7McFadyen MC,McLeod HL,Jackson FC,Melvin WT,Doehmer J,Murray GI.Cytochrome P450 CYP1B1 protein expression:a novel mechanism of anticancer drug resistance.Biochem Pharmacol 2001;62:207-212.
  • 8Rochat B,Morsman JM,Murray GI,Figg WD,McLeod HL.Human CYP1B1 and anticancer agent metabolism:mechanism for tumor-specific drug inactivation? J Pharmacol Exp Ther 2001; 296:537-541.
  • 9Patterson LH,Murray GI.Tumour cytochrome P450 and drug activation.Curr Pharm Des 2002; 8:1335-1347.
  • 10McFadyen MC,Melvin WT,Murray GI.Cytochrome P450 enzymes:novel options for cancer therapeutics.Mol Cancer Ther 2004; 3:363-371.

二级参考文献29

  • 1[1]Takiuchi H, Ajani JA. Uracil-tegafur in gastric carcinoma: a comprehensive review. J Clin Oncol, 1998; 16:2877~2885.
  • 2[2]Lu Z, Zhang R, Diasio RB. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver:population characteristics, newly identified deficient patients and clinical implication in 5-fluorouracil chemotherapy. Cancer Res,1993; 53:5433~5438.
  • 3[3]Ridge SA, Sludden J, Wei X, et al. Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer. Br J Cancer,1998; 77:497 ~ 500.
  • 4[4]Etienne MC, I agrange JI, Dassonville O, et al. A population study ofdihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol,1994; 12:2248 ~ 2253.
  • 5[5]Milano G, Etienne MC. Potential importance of dihydropyrimidine dehydrogenase in cancer chemotherapy. Pharmacogenetics, 1994;4:301 ~ 306.
  • 6[6]Ridge SA, Sludden J, Wei X, et al. Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer. Br J Cancer,1998; 77:497 ~ 500.
  • 7[7]Ridge SA, Sludden J, Brown O, et al. Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects. Br J Clin Pharmacol, 1998; 46:151~156.
  • 8[8]Wei X, MeLeod HL, MeMurrough J, et al. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest, 1996; 98:610 ~ 615.
  • 9[9]McLeod HL, Sludden J, Murray GI, et al. Characterization dihydropyrimidine dehydrogenase in human colorectal tumor. Br J Cancer, 1998; 77:461 ~ 465.
  • 10[10]Rustum YM, Harstrick A, Cao S, et al. Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors. J Clin Oncol, 1997; 15:389~400.

共引文献7

同被引文献62

  • 1Yan, Feng,Wang, Xiao-Min,Liu, Zhong-Chen,Pan, Chao,Yuan, Si-Bo,Ma, Quan-Ming.JNK1,JNK2,and JNK3 are involved in P-glycoprotein-mediated multidrug resistance of hepatocellular carcinoma cells[J].Hepatobiliary & Pancreatic Diseases International,2010,9(3):287-295. 被引量:14
  • 2宋玉成,夏薇,江金花,王庆端.盐酸千金藤素逆转EAC/ADR细胞多药耐药性的作用及其机制[J].药学学报,2005,40(3):204-207. 被引量:13
  • 3关云艳,欧希龙,郭庆明,颜芳.P-gp,ToPoⅡ和GST-π在胃癌组织中的表达及与预后的关系[J].世界华人消化杂志,2006,14(35):3371-3376. 被引量:21
  • 4Ferlay J., Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008[J]. Int.J.Cancer, 127 (12) : 2 893-2 917.
  • 52010版NCCN结肠癌指南[G].
  • 6Furusawa S, Wu J. The effects of biscoclaurine alkaloid cepharan- thine on mammalian cells: implications for cancer, shock, and in- flammatory diseases[J]. Life Sci., 2007,80:1 73 - 1 079.
  • 7Seubwai W, Vaeteewoottacham K, Hiyoshi M, et al. Cepharanthine exerts antitumor activity on cholangiocarcinoma by inhibiting NF-kappaB[J]. Cancer Sci, 2010,101 (7) : 1 590-1 595.
  • 8Biswas K K, Tancharoen S, Sarker K P, et al.Cepharanthine triggers apoptosis in a human hepatocellular carcinoma cell line (I-IuH-7) through the activation of JNK1/2 and the downregulation of Akt[J]. FE BS Lett, 2006,580 ( 2 ) : 703 -710.
  • 9Harada T, Harada K, Ueyama Y.The enhancement of tumor radiore~ sponse by combined treatment with cepharanthine is accompanied by the inhibition of DSIA damage repair and the induction of apopto- sis in oral squamous cell carcinoma[J]. Int J Oncol, 2012141 (2) : 565-572.
  • 10Kim HR, Kim S, Kim EJ, et al. Suppression of Nrf2-driven heme- oxygenase-1 enhances the chemosensitivity of lung cancerA549 cells toward cisplatin[J]. Lung Cancer, 2008,60( 1 ) : 47-56.

引证文献3

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部